+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 142 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5641375
Description Jump to:

The neurological diseases treatment market is observed as the most diversified and competitive market comprising large number of players globally. The key driving factors assisting the growth of these two segments are rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to presence of strong drug pipeline is expected to impact the market share of traditional drug treatments and further boost the overall growth of this market. Rising research and development activities in the field of neurology has been the key driver for neurological diseases treatment market and is expected to fuel its growth throughout the forecast period (2022-2030). The neurological diseases treatment market is expected to grow at a CAGR of 5.1% during the forecast period 2022-2030.

Anticholinergic and Antiepileptic Segment Led the Market revenues in 2021

The anticholinergic and antiepileptic segment alone contribute to over 44% of the revenue share in 2021. This is largely due to increased focus on R&D in these drugs segment and its application in controlling muscle movement. Increasing prevalence of neurological disorders remains as the key driver to market growth.

Treatment for Alzheimer’s Top the Market Revenues

Based on therapeutic segment, Alzheimer’s disease dominated the market segment in 2021. Intense R&D initiatives are the key reason for the largest share of Alzheimer’s segment, apart from other drivers such as increasing prevalence rate across the globe. Alzheimer’s is also expected to retain its top position throughout the forecast period. Parkinson’s disease remains as the second largest market for neurological treatment drugs market.

APAC to Grow the Fastest

After scrutiny of the neurological diseases treatment market, regional trends, market sizes, and the overall growth paired with the latest and anticipated events, Asia Pacific is observed to be the most attractive region for the neurological diseases treatment market owing to a swift growth in the uptake of medicines to prevent surging disabilities, death and to improvise on quality of living.

Drug Approvals and Pipelines Remain the Key Focus Area Among the Top Players

It is evident that drug related activities are the most preferred strategy among the top players. Drug related activities include drug approval across various geographies, presenting clinical trial outcomes, receiving permission to launch neurology drugs in various phases of clinical trials. Strategies such as mergers and acquisitions and partnerships & collaborations are comparatively insignificant in this market. Other strategies include receiving recognitions, creating awareness, participation in neurology related events and so on. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis, GSK, Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. Key data points that enables the estimation of Neurological Diseases Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Neurological Diseases Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Neurological Diseases Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Neurological Diseases Treatment market?
  • Which is the largest regional market for Neurological Diseases Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Neurological Diseases Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Neurological Diseases Treatment market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Painful Diabetic Neuropathy Drugs Market
2.2. Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021 (US$ Million)
2.3. Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021 (US$ Million)
2.4. Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021 (US$ Million)
2.5. Global Painful Diabetic Neuropathy Drugs Market, By Geography, 2021 (US$ Million)
2.6. Global Painful Diabetic Neuropathy Drugs Market, By Impact of COVID-19, 2020 (US$ Million)
2.7. Key Investment Proposition by Geography, 2021
2.8. Competitive Analysis
2.9. Key Industry Strategies
2.10. Tier Analysis 2021 Versus 2030
2.11. Key Buying Criteria
2.12. Key Case Reports
2.13. Scenario Analysis
2.14. Optimistic estimates and analysis
2.15. Realistic estimates and analysis
2.16. Pessimistic estimates and analysis
2.17. Market Profiling
2.18. Sales and Marketing Plan
2.19. Heptalysis Analysis
2.20. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
2.21. Top Market Conclusions
2.22. Strategic Recommendations

3. Painful Diabetic Neuropathy Drugs Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Painful Diabetic Neuropathy Drugs Market Value, 2020-2030, (US$ Million)
3.3. Key Trends Analysis
3.4. Market Dynamics
3.4.1. Market Drivers
3.4.2. Market Restraints
3.4.3. Key Challenges
3.4.4. Key Opportunities
3.5. Impact Analysis of Drivers and Restraints
3.6. See-Saw Analysis
3.7. Attractive Investment Proposition
3.8. Porter’s Five Force Model
3.8.1. Supplier Power
3.8.2. Buyer Power
3.8.3. Threat Of Substitutes
3.8.4. Threat Of New Entrants
3.8.5. Competitive Rivalry
3.9. PESTEL Analysis
3.9.1. Political Landscape
3.9.2. Economic Landscape
3.9.3. Technology Landscape
3.9.4. Legal Landscape
3.9.5. Social Landscape
3.10. Competitive Landscape
3.10.1. Market Positioning of Key Painful Diabetic Neuropathy Drugs Market Vendors
3.10.2. Strategies Adopted by Painful Diabetic Neuropathy Drugs Market Vendors

4. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Anticonvulsants
4.3.2. Tricyclic antidepressants
4.3.3. Serotonin-norepinephrine reuptake inhibitors
4.3.4. Opioid
4.3.5. Topical medications
4.3.6. Selective serotonin reuptake inhibitors

5. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Peripheral
5.3.2. Focal
5.3.3. Proximal
5.3.4. Autonomic

6. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Online Pharmaceuticals
6.3.2. Retail Pharmacy stores
6.3.3. Hospitals
7. North America Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
7.5.1.North America
7.5.1.1. U.S.
7.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.1.2. Canada
7.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.1.3. Rest of North America
7.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)

8. UK and European Union Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
8.5.1.UK and European Union
8.5.1.1. UK
8.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.2. Germany
8.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.3. Spain
8.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.4. Italy
8.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.5. France
8.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.6. Rest of Europe
8.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)

9. Asia Pacific Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
9.5.1.Asia Pacific
9.5.1.1. China
9.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.2. Japan
9.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.3. India
9.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.4. Australia
9.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.5. South Korea
9.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.6. Rest of Asia Pacific
9.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)

10. Latin America Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
10.5.1.Latin America
10.5.1.1. Brazil
10.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.1.2. Mexico
10.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.1.3. Rest of Latin America
10.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)

11. Middle East and Africa Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
11.5.1.Middle East and Africa
11.5.1.1. GCC
11.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.1.2. Africa
11.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.1.3. Rest of Middle East and Africa
11.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)

12. Company Profiles
12.1. Daiichi Sankyo Company, Limited
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Eli Lilly and Company
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Johnson & Johnson Services, Inc
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Pfizer Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Grunenthal GmbH
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. ViroMed Co.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Collegium Pharmaceutical, Inc
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Acorda Therapeutics, Inc
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Zydus Pharmaceuticals
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Mallinckrodt, Inc
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Macleods Pharmaceuticals Ltd.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Lupin Pharmaceuticals
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives

List of Figures
Figure 1 Global Painful Diabetic Neuropathy Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Painful Diabetic Neuropathy Drugs Market: Quality Assurance
Figure 5 Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021
Figure 6 Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021
Figure 7 Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021
Figure 8 Global Painful Diabetic Neuropathy Drugs Market, By Geography, 2021
Figure 9 Market Geographical Opportunity Matrix - Global Painful Diabetic Neuropathy Drugs Market, 2021
Figure 10 Market Positioning of Key Painful Diabetic Neuropathy Drugs Market Players, 2021
Figure 11 Global Painful Diabetic Neuropathy Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 12 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 13 See Saw Analysis
Figure 14 PETEL Analysis
Figure 15 Key Buying Criteria: Current and Long-Term Perspective
Figure 16 Global Painful Diabetic Neuropathy Drugs Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 17 Heptalysis Analysis: Global Painful Diabetic Neuropathy Drugs Market
Figure 18 Five Whys Analysis
Figure 19 Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021 Vs 2030, %
Figure 20 Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021 Vs 2030, %
Figure 21 Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021 Vs 2030, %
Figure 22 U.S. Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 23 Canada Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 24 Rest of North America Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 25 UK Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 26 Germany Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 27 Spain Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 28 Italy Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 29 France Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 30 Rest of Europe Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 31 China Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 32 Japan Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 33 India Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 34 Australia Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 35 South Korea Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 36 Rest of Asia Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 37 Brazil Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 38 Mexico Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 39 Rest of Latin America Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 40 GCC Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 41 Africa Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030
Figure 42 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020-2030

List of Tables
Table 1 Global Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 2 Global Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 3 Global Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 4 North America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 5 North America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 6 North America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 7 U.S. Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 8 U.S. Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 9 U.S. Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 10 Canada Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 11 Canada Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 12 Canada Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 13 Rest of North America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 14 Rest of North America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 15 Rest of North America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 16 UK and European Union Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 17 UK and European Union Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 18 UK and European Union Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 19 UK Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 20 UK Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 21 UK Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 22 Germany Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 23 Germany Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 24 Germany Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 25 Spain Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 26 Spain Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 27 Spain Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 28 Italy Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 29 Italy Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 30 Italy Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 31 France Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 32 France Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 33 France Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 34 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 35 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 36 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 37 Asia Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 38 Asia Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 39 Asia Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 40 China Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 41 China Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 42 China Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 43 Japan Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 44 Japan Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 45 Japan Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 46 India Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 47 India Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 48 India Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 49 Australia Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 50 Australia Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 51 Australia Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 52 South Korea Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 53 South Korea Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 54 South Korea Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 55 Latin America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 56 Latin America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 57 Latin America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 58 Brazil Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 59 Brazil Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 60 Brazil Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 61 Mexico Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 62 Mexico Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 63 Mexico Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 64 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 65 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 66 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 67 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 68 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 69 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 70 GCC Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 71 GCC Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 72 GCC Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 73 Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 74 Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 75 Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
Table 76 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
Table 77 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
Table 78 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)

Companies Mentioned

  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co.
  • Bayer AG
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Zogenix Inc.
  • Eisai Co. Ltd.
  • AZTherapies Inc.
  • Biogen Inc.
  • Intra-Cellular Therapies Inc.
  • Avid Radiopharmaceuticals
  • Avanir Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Sunovion Pharmaceuticals Inc.
  • AbbVie Inc.
  • NeuroDerm Ltd.
  • MedDay Pharmaceuticals SA

Related Topics

Related Reports

Neurological Disease Treatment Market Report and Forecast 2024-2032 - Product Image

Neurological Disease Treatment Market Report and Forecast 2024-2032

  • Report
  • 240 Pages
  • Global
From
Rare Neurological Disease Treatment Global Market Report 2024 - Product Image

Rare Neurological Disease Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Microbiome in Neurological Disease. International Review of Neurobiology Volume 167 - Product Image

Microbiome in Neurological Disease. International Review of Neurobiology Volume 167

  • Book
  • Global
Sex and Gender Differences in Neurological Disease. International Review of Neurobiology Volume 164 - Product Image

Sex and Gender Differences in Neurological Disease. International Review of Neurobiology Volume 164

  • Book
  • Global
The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part II - Spinal Cord and Peripheral Motor and Sensory Systems. Edition No. 3. Netter Green Book Collection - Product Image

The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part II - Spinal Cord and Peripheral Motor and Sensory Systems. Edition No. 3. Netter Green Book Collection

  • Book
Copyright © 2002-2024 Research and Markets. All Rights Reserved.